Pricing Log in Create free account

Celyad SA (CYAD) vs Impact Biomedical Inc. (IBO)

Celyad SA and Impact Biomedical Inc. are both Biotechnology companies. Impact Biomedical Inc. is the larger, with a market value of $27.0M against $23.8M — 1.1× the size. Celyad SA has negative trailing earnings, so its P/E is not meaningful; Impact Biomedical Inc. trades at 0.2×. Impact Biomedical Inc. has the higher net margin (2,254.3% vs 0.00%) and the lower return on invested capital (−22.8% vs 0.00%). Across the 12 metrics below, Celyad SA leads on 6 and Impact Biomedical Inc. on 6.

Valuation

Metric CYAD IBO Biotechnology median
P/E n/m 0.24 8.50
P/S n/m 653.87 9.71
P/B 11.18 1.63 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA — n/m 0.64
EV/Sales — 881.33 9.21
Earnings yield (708.87%) 415.59% (33.15%)
Free cash flow yield (438.06%) (2.30%) (25.50%)

Profitability

Metric CYAD IBO Biotechnology median
Gross margin 0.00% (1,111.43%) 65.16%
Operating margin — (14,600.00%) 0.00%
Net margin 0.00% 2,254.29% 0.00%
Free cash flow margin 0.00% (1,451.43%) 0.00%
Return on equity 0.00% 24.01% (56.36%)
Return on assets 0.00% 4.41% (48.04%)
Return on invested capital 0.00% (22.81%) 0.00%

Growth

Metric CYAD IBO Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 113.33% 83.48% 30.26%
Revenue growth, 5-year CAGR (63.51%) — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CYAD IBO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.94 0.16 4.72
Net debt to EBITDA (1.62) 0.00 0.96

Dividend

Metric CYAD IBO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CYAD IBO Biotechnology median
Market cap 23.79m 26.99m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack